Bailong Chuangyuan(SH:605016) GUOTAI HAITONG SECURITIES·2026-01-23 05:45Investment Rating - The investment rating for the company is "Accumulate" [4]. Core Insights - The company is expected to show significant revenue growth with a notable acceleration in net profit, indicating a high quality of growth and sustained potential for continued expansion [1]. - The financial forecast indicates a strong increase in total revenue from 868 million in 2023 to 2,200 million by 2027, with a compound annual growth rate (CAGR) of 26.1% [3]. - The net profit attributable to the parent company is projected to rise from 193 million in 2023 to 637 million in 2027, reflecting a CAGR of 32.8% [3]. - The earnings per share (EPS) is expected to increase from 0.46 yuan in 2023 to 1.52 yuan in 2027 [3]. Financial Summary - Total revenue for 2025 is estimated at 1,379 million, representing a year-on-year growth of 19.8% [3]. - The net profit for 2025 is projected at 366 million, with a year-on-year increase of 48.9% [3]. - The company’s return on equity (ROE) is expected to improve from 12.8% in 2023 to 21.3% in 2027 [3]. - The price-to-earnings (P/E) ratio is forecasted to decrease from 48.92 in 2023 to 14.82 in 2027, indicating a more attractive valuation over time [3]. Market Data - The target price for the company's stock is set at 31.90 yuan, up from a previous target of 30.16 yuan [4]. - The company's market capitalization is approximately 9,442 million [5]. - The stock has traded within a range of 16.17 to 28.55 yuan over the past 52 weeks [5]. Growth Drivers - The company is experiencing increased demand for its high-margin resistant dextrin products, which are contributing to profit growth [10]. - The expansion of production capacity and optimization of product structure are expected to alleviate capacity constraints and enhance profitability [10]. - The company is well-positioned to capitalize on the growing health-conscious consumer trends, particularly with its alulose and prebiotic products [10].